Can Systemic Candida glabrata Present with Small White Lesions in the Ileum?
Yes, systemic Candida glabrata infection can present with intestinal lesions including in the ileum, though this manifestation is uncommon and typically occurs in severely immunocompromised patients.
Clinical Presentation and Pathophysiology
Gastrointestinal Candida infections, including those caused by C. glabrata, can affect any segment of the GI tract from esophagus to colon. While esophageal involvement is most common, intestinal candidiasis does occur and has been documented 1. The characteristic white lesions you're asking about represent fungal colonization and invasion of the intestinal mucosa.
In experimental models of disseminated candidiasis, severe ulceration of the ileal mucosa has been observed overlying regions of colonization and necrosis of gut-associated lymphoid tissue 2. These intestinal lesions likely serve as the portal of entry for systemic dissemination, with organisms escaping through damaged mucosa into lymphatic vessels and bloodstream.
Species-Specific Considerations for C. glabrata
C. glabrata is the second most common cause of invasive candidiasis worldwide 3. While most documented cases of symptomatic esophageal and intestinal candidiasis involve C. albicans, C. glabrata can cause symptomatic GI infections 4. In fact, the first documented case of Candida colitis caused specifically by C. glabrata was reported in 2019, presenting with diarrhea, rectal bleeding, and septic shock 5.
C. glabrata has unique characteristics that facilitate GI colonization:
- It has adapted to colonize all segments of the human GI tract 6
- During intestinal inflammation, C. glabrata undergoes cell wall remodeling with increased chitin content 6
- It exhibits immune evasion strategies that help establish persistent infections 7
High-Risk Patient Populations
Intestinal candidiasis with C. glabrata is most likely in:
- Severely immunocompromised patients (advanced HIV, chemotherapy recipients)
- Patients with underlying GI pathology (inflammatory bowel disease, recent GI surgery)
- Those with prolonged broad-spectrum antibiotic exposure
- Patients with diabetes or other metabolic disorders 5, 1
Diagnostic Approach
The diagnosis requires both visualization of characteristic yeast or mycelial forms AND positive fungal culture from endoscopic biopsies 1. Key diagnostic steps include:
- Endoscopic examination with biopsy of suspicious lesions
- Histological examination to identify fungal elements invading tissue (not just surface colonization)
- Fungal culture to identify the specific Candida species - this is critical since C. glabrata has different antifungal susceptibility patterns than C. albicans 5
- Blood cultures if systemic dissemination is suspected
- Antifungal susceptibility testing is essential for C. glabrata given its intrinsic reduced azole susceptibility 4, 3
Treatment Implications
For proven invasive C. glabrata infection, an echinocandin (caspofungin, micafungin, or anidulafungin) is the recommended first-line therapy 8, 4. This is particularly important for C. glabrata because:
- C. glabrata exhibits intrinsic reduced susceptibility to fluconazole 3
- Approximately 10% of clinical isolates show co-resistance to both azoles and echinocandins 7
- Echinocandins have demonstrated high susceptibility rates in recent surveillance data 9
For multidistrict or refractory C. glabrata infections, combination therapy with an echinocandin plus liposomal amphotericin B may be necessary when monotherapy fails 10.
Critical Caveats
- Distinguishing colonization from true infection is essential - mere presence of Candida in stool or superficial swabs is insufficient for diagnosis
- The white lesions must show tissue invasion on histology, not just surface colonization
- C. glabrata intestinal infections are rare; consider alternative diagnoses first
- Always obtain susceptibility testing as resistance patterns vary significantly by geographic region 9